多巴胺替代的皮质效应导致帕金森病的临床反应变化
Alex I Wiesman1, Mikkel C Vinding2,3, Panagiota Tsitsi2
1Department of Biomedical Physiology & Kinesiology, Simon Fraser University, Burnaby, Canada.
medRxiv : the preprint server for health sciences
|November 28, 2024
概括
帕金森病 (PD) 治疗反应的个体变化与多巴胺替代疗法 (DRT) 如何影响大脑活动有关. 皮质β活性中较大的DRT诱导的变化与PD患者的临床改善相相关.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 临床神经学 临床神经学
背景情况:
- 对多巴胺替代疗法 (DRT) 的反应的个体变异性阻碍了有效的帕金森病 (PD) 治疗.
- 了解这种变化的神经生物学来源对于推进PD干预至关重要.
研究的目的:
- 在PD患者中绘制个人皮质神经生理反应对DRT的地图.
- 调查DRT诱导的皮质活动变化与临床结果之间的联系.
主要方法:
- 在DRT之前和之后的PD患者的磁脑电图 (MEG) 数据.
- 整合患者特异性DRT反应图与皮质多巴胺受体/输送体密度图谱.
- 通过DRT进行节律β活性调节的分析.
主要成果:
- 皮质β活性DRT诱导的增强与多巴胺丰富的皮质区域有关.
- 较大的β活性增强与PD患者临床改善的减少相关.
- 这表明一个神经生理机制背后的变量DRT响应.
结论:
- 这些发现阐明了PD神经生理学变化的多巴胺基基础.
- 方法方法提供了一个框架,用于将药物对皮质神经生理学的影响置于背景中.
- 这可以为个性化PD治疗的未来研究和临床应用提供信息.
相关概念视频
Parkinson's Disease: Treatment
220
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
220
Parkinson's Disease: Overview
482
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
482
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Factors Affecting Drug Response: Overview
1.9K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.9K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
226
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
226
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165


